@crispinhiley @_ShankarSiva @tom_dilling @Mat_Guc @gerryhanna @DrewMoghanaki @BrendonStilesMD @umbertoricardi @HoudaBahig @DrAlexLouie We had 5 participants with PD-L1 TPS of at least 90%, and PD-L1 TPS did not seem to be a prognostic factor in patients treated with pembroRT.

@JCO_ASCO @nitinohri @DrSteveMartin FYI these waterfall plots depict responses to induction immunotherapy before starting radiotherapy. Smaller RT volumes and no concurrent chemotherapy made this regimen extremely well-tolerated. Our next paper will focus on patient-reported outcomes from this trial.

@BrendonStilesMD Induction chemotherapy and use of q3week chemotherapy in these patients may have led to more toxicity.

@DrSteveMartin @BrendonStilesMD @JCO_ASCO @EinsteinMed @MontefioreNYC @ShirishGadgeel @ElaineShumMD @JSabari @_ShankarSiva @JeffBradleyMD @SBRT_CR @ASTRO_org @ASCOPost @StephenVLiu Thanks to @QuadShotNews for highlighting our trial today!

@BrendonStilesMD @DrSteveMartin @JCO_ASCO @EinsteinMed @MontefioreNYC @ShirishGadgeel @ElaineShumMD @JSabari @_ShankarSiva @JeffBradleyMD @SBRT_CR @ASTRO_org @ASCOPost @StephenVLiu Thank you to all of our collaborators, to the trial sponsors, and especially to the study participants! It is an honor to be part of such a strong team that is dedicated to advancing cancer care.

@BrendonStilesMD @5_utr COAST participants had to have measurable disease after chemoRT. That could explain the poor outcomes for the control group.

@DrewMoghanaki @ldawsonmd Here is a similar trial worth checking out

@BrendonStilesMD @DrSteveMartin @Latinamd I’m glad we all play on the same team - even if someone is occasionally hit by friendly fire.

@BrendonStilesMD Could we be too focused on number of involved LN stations and stage group? I don’t think these factors identify the LA-NSCLC patients who benefit from surgery, which is the key question.

@DrewMoghanaki @DrSteveMartin @BrendonStilesMD @JeffBradleyMD @finn_corinne @gerryhanna @DrAlexLouie @Mat_Guc @StevenLin_MDPhD @SBRT_CR @samsonpp @AdelZakharia I agree that this adds to the evidence supporting early use of immunotherapy for intact tumors in patients with intact immune systems (like in our SPRINT trial) and trying new strategies to control large tumors (like in NRG-LU008).

@_ShankarSiva @BrendonStilesMD I think our main role is to break up fights about adjuvant chemotherapy for 4.1 cm pT2N0 NSCLCs.